Company ProfilePremium

Cellid, Co., Ltd.

Company Profile Analysis

Ticker: 299660.KQ주식회사 셀리드

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cellid, Co., Ltd. - Company showcase

Year Founded & Workforce

2006

49 Employees

Cellid, Co., Ltd. logo

Cellid, Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cellid, Co., Ltd. Overview

Cellid is a Korean clinical-stage immunotherapy company built on CeliVax. CeliVax is a cell-based cancer vaccine platform that loads tumour antigens into a patient's own B cells and monocytes using an adenoviral vector, and adds the NKT-cell adjuvant α-galactosylceramide. The company listed on KOSDAQ in 2019 on the strength of its HPV-cancer vaccine BVAC-C.

From 2020 it redirected most of its capital into an adenovirus-vector COVID-19 vaccine. In June 2026 that vaccine (AdCLD-CoV19-1 OMI) failed to show non-inferiority to Pfizer's Comirnaty in a global Phase 3 trial. Cellid has had no meaningful drug revenue since listing. Its reported revenue now comes almost entirely from ForBaker, a bakery e-commerce business it absorbed in 2024 to meet KOSDAQ revenue-maintenance thresholds.

With cash falling, short-term borrowings rising and its lead asset impaired, Cellid agreed in September 2026 to cede control to Huniverse Global. Huniverse is a medical-IT company backed by Korea University's technology holding company and plans data-driven personalised cancer vaccines.


What the company does

Cellid runs three activities. The first, R&D, is its reason for existing. The second produces nearly all of its revenue. The third is small and still developing.

  1. Biopharmaceutical R&D (core, pre-revenue).

    • CeliVax-based therapeutic cancer vaccines (the BVAC family).

    • Adenovirus-vector prophylactic vaccines, mainly COVID-19.

    • The platform uses autologous B cells and monocytes as antigen-presenting cells. Antigen genes are delivered by a replication-incompetent adenovirus, and α-galactosylceramide is added to activate NKT cells.

    • Manufacturing takes about one day per batch (company disclosure at IPO, 2019).

  2. E-commerce / bakery (revenue-generating). This is the ForBaker business, acquired in March 2024 for about KRW 12 and merged by absorption in 2024. It produced 91.4% of FY2024 revenue and about 99.97% of FY2025 revenue.

  3. Contract manufacturing / CDMO services (emerging, immaterial).

    • GMP production and quality-analysis services for viral vectors and cell and gene therapies, run from the Seongnam GMP centre.

    • CMO revenue was KRW 3.15 in Q1 2024 and only KRW 0.03 in Q1 2025.

    • A June 2025 MOU with AltiCure led to a stability-testing and product-storage contract on 2 Sep 2026. The contract value was not disclosed.

Business and revenue model

Revenue typeStatusEvidence
Product sales (drugs)None. No product has been approved.Revenue was KRW 0 in FY2023 (DART)
Licensing / milestonesHistoric upfront payments only: KRW 10 from LG Chem (2021) and an early US-only BVAC-C licence to NeoImmuneTech (2014). Milestones of up to KRW 1,825 from LG Chem are contingent.Company release, 26 May 2021
Contract manufacturing (CMO/CDMO)Sporadic and small8.6% of FY2024 revenue; 0.2% of Q1 2025 revenue
Merchandise (bakery e-commerce)About 100% of current revenueFY2025 revenue of KRW 88.4, almost all e-commerce
Subscription——

Value-chain position and customers

Cellid sits at the discovery, translational and clinical-development stages of the biopharma value chain. It also has in-house GMP manufacturing for clinical supply.

Its intended end customers are:

  • Oncology patients and hospitals, for HPV-positive cervical, head-and-neck and other cancers.

  • National immunisation and booster programmes, for COVID-19. The company had said it would target developing countries with a lower-cost adenoviral vaccine.

  • Biotech developers that need viral-vector CDMO services.

The bakery segment sells to consumers through online channels.

Company self-description vs. independent characterisation

Company self-description (paraphrased): a "leader in cell-based immunotherapy" that develops immunotherapeutic vaccines for cancer and infectious diseases on its proprietary CeliVax platform.

Independent characterisation: Cellid is a capital-constrained, single-platform biotech whose most advanced programme has failed. It has relied on four equity raises in four years (2023–2026), a bakery acquisition to stay above KOSDAQ revenue thresholds, and now a change of control.

What remains of scientific value is concentrated in three areas:

  • BVAC-C plus durvalumab in second-line cervical cancer.

  • BVAC-E6E7 in HPV-positive head-and-neck cancer.

  • The LG Chem-partnered neoantigen programme (BVAC-Neo), which is still preclinical.

Strategy

Stated strategy themes (company statements, paraphrased)

2019 IPO: become a global immunotherapy company through the CeliVax platform. Out-license one asset a year from 2019 to 2022 (BVAC-Neo in 2019, BVAC-B in 2020). Seek conditional approval of BVAC-C by 2021.

2020–2025: achieve "vaccine sovereignty" for Korea with a domestically developed adenoviral COVID-19 vaccine priced at less than half of mRNA vaccines and aimed at developing markets. Seek MFDS and WHO approvals.

2024 onward: "select and focus" on the programmes most likely to succeed. Diversify revenue through bakery and potential health functional foods. Stabilise earnings through CMO/CDMO.

Delivery against targets: none of the 2019 out-licensing targets were met on time. The BVAC-Neo licence to LG Chem came in 2021. BVAC-C did not reach conditional approval by 2021, and the COVID-19 vaccine failed Phase 3.

Initiatives in the last 24 months

InitiativeDateDetailsStatus
Omicron COVID-19 Phase 3 completion and approval filing2025 – Jun 2026Planned MFDS filing (as stated on 18 Jun 2026)Failed (26 Jun 2026). The company says it is reviewing a supplementary trial.
LP.8.1 strain-updated booster2,026Phase 2 INDReturned/rejected by the regulator
Viral-vector CDMO "one-stop" platform with AltiCureMOU 16 Jun 2025; first contract 2 Sep 2026Joint R&D-to-GMP offering; localisation of vector technologyEarly stage; contract value undisclosed
BVAC-E6E7 head-and-neck Phase 12024–2026Selected as a government-funded national projectOngoing
Magok HQ and R&D centre2023–2026KRW 235.4 consortium investment through PFCompleted
Change of control to Huniverse Global; personalised cancer vaccines using medical dataSigned 21 Sep 2026Huniverse's precision-medicine hospital information system and data infrastructure to be combined with the BVAC pipeline; joint platform; KRW 100 to fund existing R&D, clinical trials and the platform; further CB financing plannedPending (payment due 9 Nov 2026)
Bakery-to-health-food pivotStated Jun 2024Possible conversion of the bakery business into health functional foodsNo disclosed progress

ESG commitments: none disclosed.

Cost programmes: none with quantified targets were disclosed.

Medium-term targets and guidance

No quantitative financial guidance is publicly disclosed. Management has given no revenue, breakeven or cash-runway guidance in the sources reviewed.

Products & Services

Platform technologies

PlatformDescriptionStatus
CeliVaxAutologous B cells and monocytes are transduced with antigen genes by adenovirus and loaded with α-galactosylceramide, which activates NKT cells. The aim is to engage innate immunity (NK/NKT) and adaptive immunity (CD8+ T cells, antibodies) together. Manufacturing takes about one day.Core oncology platform. Clinical proof of concept in cervical cancer.
Replication-incompetent adenovirus vector platformProprietary adenoviral vector and high-yield producer cell line. Used for prophylactic vaccines and as the CeliVax gene-delivery tool.Supported the COVID-19 programme. Now marketed for CDMO use.
GMP CDMO capabilityGMP-grade production of viral vectors and cell and gene therapies, plus quality-control analyticsEarly commercialisation (AltiCure contract, 2026)

Oncology pipeline (BVAC family, CeliVax-based)

ProductAntigen / targetIndicationsStage (latest disclosed)Key dataPartner
BVAC-C (monotherapy and + topotecan)HPV16/18 E6/E7Recurrent/metastatic cervical cancer after platinum chemotherapyPhase 1/2a completed (NCT02866006)ORR 21% (n=14), median DoR 18 months, DCR 43% (ASCO 2021). Peer-reviewed in Frontiers in Immunology (2024).US rights historically licensed to NeoImmuneTech (2014).
BVAC-C + durvalumab (DURBAC)HPV16/18 E6/E7 + anti-PD-L1Second-line HPV16/18+ cervical cancerPhase 2 (NCT04800978); six Korean centresORR 37.9% (5 CR, 6 PR), median PFS 8.7 months, 6-month PFS 51.7%; ORR 52.9% if treatment-free interval >6 months; grade 3–4 AEs 13% (SGO 2025)Durvalumab is AstraZeneca's drug. Supply arrangement not detailed in sources.
BVAC-E6E7HPV16/18 E6/E7 (next-generation construct)Unresectable recurrent/metastatic HPV16/18+ head-and-neck squamous cell carcinomaPhase 1, under a selected national R&D grantNot yet reported—
BVAC-BHER2/neuHER2+ gastric cancer; planned breast, ovarian, lung, pancreaticPhase 1 approved Jan 2018 (Severance). reported as deprioritised under a 2024 "select and focus" strategy.——
BVAC-PPAP, PSMAProstate cancer, renal cell carcinoma, glioblastomaPreclinical (2019 disclosure)——
BVAC-Mgp100 / MAGE-A3Melanoma, lung and colorectal cancerPreclinical (2019 disclosure)——
BVAC-NeoPatient-specific neoantigensPan-tumour personalised vaccinePreclinical. A third-party report says there has been no clinical entry about five years after licensing.—LG Chem (global exclusive, 2021). Syntekabio AI-prediction MOU (2019).

Infectious-disease pipeline (adenovirus vector)

ProductDescriptionStageKey data
AdCLD-CoV19 (original)Single-dose adenoviral COVID-19 vaccinePhase 1/2a IND Dec 2020. Superseded.Strong antibody responses in mouse and monkey studies (company, 2020)
AdCLD-CoV19-1Improved-productivity vector versionPhase 2b terminated early in 2022Recruitment failure
AdCLD-CoV19-1 OMIOmicron boosterGlobal Phase 3 completed. Primary endpoint missed (26 Jun 2026).GMT ratio 0.42 vs. Comirnaty (lower 95% CI 0.38 vs. non-inferiority margin 0.67). Seroresponse 17.12% vs. 42.64% (difference −25.51 pp vs. −10 pp margin). No serious ADRs reported. Planned enrolment was 4,000 (Cohort A 1,200 immunogenicity; Cohort B 2,800 safety).
AdCLD-CoV19-1 LP.8.1Strain-updated boosterPhase 2 IND filed and returned/rejected in 2026—
Multivalent COVID-19 vaccineMentioned as a use of 2023 rights-offering fundsStatus not disclosed—

Non-pharma products and services

OfferingDescriptionTarget customerPricing
ForBaker bakery products (e-commerce)Bakery franchise and online sales.Consumers—
CDMO servicesViral-vector GMP production, stability testing, product storageBiotech and gene-therapy developers (e.g. AltiCure)Contract values not disclosed

Financial Narrative

Source for all tables: OpenDART separate statements via Valueline, Bullstory and ETFShopping, unless stated otherwise. FY = calendar year. Units are KRW 100M unless stated otherwise.

Income statement

Notes:

  • Pre-tax income equals net income because no income-tax expense was recorded.

  • Diluted EPS equals basic EPS because the company is loss-making (anti-dilutive).

  • The FY2022 net loss (−229) is far larger than the operating loss (−149), pointing to roughly KRW 80 of non-operating losses.

  • Exact FY2025 values: revenue KRW 8,841,828,282; operating income −KRW 11,343,055,983; net income −KRW 12,069,197,070 (OpenDART via Bullstory).

Margins and growth

Operating and EBITDA margins are derived. FY2023 margins are undefined because revenue was zero.

Revenue CAGR FY2021–FY2025: about 77% a year (derived: 9.1 → 88.4). This number is not meaningful as a growth measure. It reflects a switch from occasional CMO income to bakery e-commerce, not commercial progress in the pharmaceutical business.

Interim (TTM to 30 Jun 2026, Valueline):

  • Revenue KRW 104.2 and operating loss KRW −103.4.

  • Net loss KRW −273.8, including KRW 171.2 of asset impairment.

  • H1 2026 net loss is about KRW −205. This is derived from the fall in retained earnings from −770.7 to −975.7.

  • Development-cost assets fell from KRW 288.5 to KRW 147.0, consistent with impairment of capitalised COVID-19 vaccine development after the Phase 3 failure.

Balance sheet

Notes:

  • Net debt and working capital are derived.

  • FY2021 cash comes from ETFShopping.

Cash flow

Notes:

  • Equity raises come from DailyPharm (Sep 2026) and the MedigateNews and Asiae deal coverage.

  • Capex and free cash flow: not publicly disclosed in the sources reviewed. Proxies are the rise in construction-in-progress (KRW 4.3 → 68.4 → 135.1 → 280.1, FY2022–FY2025) and the final Magok investment of KRW 235.4 (DART). Free cash flow was clearly and materially negative in every year.

  • TTM operating cash flow to Q1 2026 was −77.3 (Valueline).

Ratios

Notes:

  • ROE, ROA, debt-to-equity and asset turnover are derived using average balances.

  • Liabilities-to-equity comes from ETFShopping.

  • Not meaningful: ROIC, net debt/EBITDA and interest coverage are all n/m because EBIT and EBITDA are negative. FY2025 interest expense was KRW 1.4 and interest income KRW 3.2 (Valueline).

  • Cash conversion cycle: not publicly disclosed. FY2025 inventory was KRW 1.9 and trade receivables KRW 3.1, both immaterial.

Commentary on trends, inflections and drivers

Structural loss rate. Operating losses have stayed in a narrow band of KRW 113–149 a year for five years. The improvement since FY2022 reflects two things:

  • Bakery gross profit (about KRW 15.7 in FY2025).

  • Capitalisation of COVID-19 Phase 3 costs. Development-cost assets rose from KRW 41.5 in FY2023 to KRW 288.5 in FY2025, so a large share of real R&D spending bypassed the income statement.

That capitalisation reversed in H1 2026. The impairment pushed the TTM net loss to about KRW −274. Reported losses in FY2023–FY2025 understated true economic cash burn, which was about KRW 100 a year in operating cash outflow plus capitalised development spend.

Funding dependence. Operating cash flow was negative by KRW 71–122 every year. Cash has been rebuilt only by raising capital:

  • IPO 2019: KRW 396.

  • CB 2021: KRW 190.

  • Rights issues 2023–2025: KRW 765 in total.

  • Placements in 2026: KRW 30 to investment associations and about KRW 100 from Huniverse.

Cumulative capital raised since the IPO is about KRW 1,349 (DailyPharm). The share count nearly tripled, from 10.71M to 29.50M, between FY2022 and FY2025.

Leverage inflection. The Magok HQ and R&D centre is a 22% consortium stake financed through project financing. It moved the balance sheet from net cash to net debt. Short-term borrowings jumped from zero (FY2024) to KRW 276.1 (FY2025) and KRW 336.3 (June 2026), probably reclassified from long-term debt as the project completed.

With cash at KRW 129.7 at June 2026, the current ratio has fallen to 0.57x. That makes refinancing, or selling or leasing out space at the Magok asset, an urgent issue. This is an analytical inference; the company has not disclosed a refinancing plan in the sources reviewed.

Equity erosion. Equity peaked at KRW 742 at FY2025 after the 2025 raise, then fell 28% in six months to KRW 536.7 because of the impairment. The FY2023 land revaluation surplus of KRW 119.7 supports book value. Price-to-book of about 1.2–1.3x therefore partly rests on revalued land.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment (KRW) and Revenue by Segment (%)

SegmentFY2021FY2022FY2023FY2024FY2025

E-commerce (bakery) revenue (KRW 100M)

00038.188.4

Bio / CMO revenue (KRW 100M)

9.14.803.60.03

Total revenue (KRW 100M)

9.14.8041.788.4

E-commerce share of revenue (%)

00091.499.97

Segment Margins & Growth (%)

MetricFY2024FY2025

Total revenue YoY growth (%)

n/m

112.3

Company gross margin (%)

—17.8

E-commerce operating margin (%)

—-2

Income Statement (KRW) and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW 100M)

9.14.8041.788.4

Cost of sales (KRW 100M)

————72.6

Gross profit (KRW 100M)

————15.7

SG&A incl. expensed R&D (KRW 100M)

————129.1

Operating income (KRW 100M)

-130-149-122-120-113

EBITDA (KRW 100M)

————-97.3

Pre-tax income (KRW 100M)

-131-229-116-123-121

Net income (KRW 100M)

-131-229-116-123-121

EPS basic (KRW)

-1,346-2,350-1,078-743-474

EPS diluted (KRW)

-1,346-2,350-1,078-743-474

Dividends per share (KRW)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

————17.8

Operating margin (%)

-1,430-3,104—-288-128

EBITDA margin (%)

————-110

Net margin (%)

-1,438-4,764—-294-137

Revenue growth YoY (%)

—-47.2-100—112.3

Balance Sheet (KRW) and Share Count (M)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW 100M)

—458.5639.2760.81,108.6

Cash & equivalents (KRW 100M)

5282.5133.890.2223.5

Current assets (KRW 100M)

—209.7168.7114.5244.2

Current liabilities (KRW 100M)

—205.3103.249.4294.2

Short-term debt incl. ST bonds (KRW 100M)

—118.754.90276.1

Long-term borrowings (KRW 100M)

—064.8130.70

Total debt (KRW 100M)

—118.7119.7130.7276.1

Net debt (KRW 100M)

—36.2-14.140.552.6

Total liabilities (KRW 100M)

—234.1234.2248.8366.6

Total equity (KRW 100M)

—224.3404.9512.0742.0

Goodwill (KRW 100M)

—008.80

Capitalised development costs (KRW 100M)

—041.5185.3288.5

Property, plant & equipment (KRW 100M)

—206.1403.3446.2568.5

Working capital (KRW 100M)

—4.465.565.1-50.0

Accumulated deficit (KRW 100M)

—-410.3-526.9-650.2-770.7

Shares outstanding (M)

10.7110.7113.6021.1029.50

Book value per share (KRW)

—2,0962,9772,4262,515

Financial Analysis

ItemKRW 100M

Total assets

968.3

Cash

129.7

Current assets

205.9

Current liabilities

358.2

Short-term borrowings

336.3

Total liabilities

431.5

Equity

536.7

Buildings (Magok, capitalised)

366.9

Development costs

147.0

Working capital (derived)

−152.3

Net debt (derived)

206.6

BPS

KRW 1,819

Cash Flow (KRW)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW 100M)

-82-122-71-103-102

Equity raised (KRW 100M, approx.)

00175232358

Convertible bonds issued (KRW 100M)

1900000

Dividends paid (KRW 100M)

00000

Share buybacks (KRW 100M)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%)

——-36.9-26.8-19.3

ROA (%)

——-21.1-17.6-12.9

Current ratio (x)

—1.021.632.320.83

Liabilities-to-equity (%)

50104584949

Debt-to-equity (x)

—0.530.300.260.37

Asset turnover (x)

——00.060.09

Revenue by Region (KRW) and Revenue by Region (%)

RegionFY2021FY2022FY2023FY2024FY2025

South Korea revenue (KRW 100M)

9.14.8041.788.4

Overseas revenue (KRW 100M)

00000

South Korea share of revenue (%)

100100100100100

Revenue by Region (KRW)

Segment × regionFY2024FY2025

E-commerce × Korea (KRW 100M)

38.188.4

Bio/CMO × Korea (KRW 100M)

3.60.03

Share Price History

DatePrice (KRW)Context

20 Feb 2019

33,000 (IPO); 43,750 (opening)

Listing

Jul 2021

About 143,103 close (9 Jul 2021); intraday above 150,000

COVID-19 vaccine peak; market cap above KRW 13,000

31 Dec 2025

2,860

Year-end

30 Apr 2026

3,180

Before the readout

30 Jun 2026

1,406

After the Phase 3 failure

20 Jul 2026

1,071

Near the 52-week low

15 Oct 2026

2,215

Latest close

Valuation Multiples

MultipleCellidPeer medianNote

P/E

n/m

n/m

Loss-making

EV/EBITDA

n/m

n/m

Negative EBITDA

EV/Sales (TTM, approx.)

8.2—

Derived: (market cap about 653 + net debt about 207) / TTM revenue 104.2

P/S (FY2025)

7.43.8

Derived: 653 / 88.4. Peer median from Alpha Distillery.

P/B (June 2026 equity)

1.220.93

Derived: 653 / 536.7

Components

ComponentValue (KRW 100M)

E-commerce

28

BVAC-C

220

BVAC-E6E7

80

COVID-19 residual

50

Sum of the parts

378

Key Events

EventFY2019FY2021FY2023FY2024FY2025

Capital raised (KRW 100M)

396190175232358

Issue price (KRW)

33,000—4,5153,0904,260

Analyst Conclusions

Guidance and consensus

MetricFY2026EFY2027E
Revenue (KRW 100M)95105
Operating loss (KRW 100M)-105-95

Management guidance: none quantitative. The company has said it will continue COVID-19 development based on the safety data and is reviewing a supplementary immunogenicity trial. After closing, Huniverse plans to fund existing R&D, clinical trials and a joint platform with the KRW 100 subscription and further CB financing.

Consensus: none available.

Independent AI estimates (Alpha Distillery, labelled): ### Bull-case arguments

  1. BVAC-C has real activity. The ORR of 37.9% and 6-month PFS of 51.7% in a second-line, post-platinum population leave room for a partnered registrational study, especially in patients with a treatment-free interval of more than 6 months (ORR 52.9%).

  2. The recapitalisation removes the overhang. About KRW 130 of fresh equity (Huniverse plus Centrust/SPE) and a planned CB could ease the June 2026 liquidity squeeze. A new board may also cut spending on the failed COVID-19 franchise.

  3. Hard-asset backstop. Land of KRW 233.8 and a Magok building of KRW 366.9 support book value. Asset monetisation could cut short-term debt and lift the effective cash runway.

Bear-case arguments

  1. The core thesis has failed. About KRW 955 was spent on COVID-19 after 2020 without approval. The GMT ratio of 0.42 is not a near-miss, and the follow-on LP.8.1 IND was already rejected.

  2. Balance-sheet fragility. A current ratio of 0.57x, KRW 336.3 of short-term debt and operating cash burn of about KRW 100 a year mean more dilution is likely even after closing. The acquirer itself has equity of only KRW 8.

  3. Valuation does not reflect fundamentals. P/S of about 7.4x on bakery revenue with negative operating margins, and P/B of about 1.2x despite equity erosion. Pricing has been driven by themes (limit-up and limit-down moves) rather than cash flows.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
9 Nov 2026Huniverse subscription payment (deal closing); board reconstitution; new CEO
Q4 2026 – H1 2027Terms and size of the follow-on CB
Q4 2026Q3 2026 quarterly report: cash, borrowings, further impairment of the remaining KRW 147.0 of development costs
2,027Supplementary COVID-19 trial decision, or a formal discontinuation
2026–2027BVAC-C registrational strategy or partnering; DURBAC survival update; BVAC-E6E7 Phase 1 data
2026–2027Any clinical entry of LG Chem's BVAC-Neo, or termination of the licence
OngoingRefinancing of short-term borrowings or a transaction on the Magok asset
OngoingAdditional CDMO contracts with disclosed values
Mar 2027FY2026 business report; KOSDAQ listing-maintenance status

Analyst verdict

Cellid is a clear example of a Korean technology-listed biotech that bet its balance sheet on a pandemic opportunity and lost.

The original CeliVax thesis was a fast-to-manufacture, autologous B-cell and monocyte vaccine that engages innate and adaptive immunity. That idea still has scientific merit. The best evidence is DURBAC, where BVAC-C plus durvalumab produced a 37.9% response rate and an 8.7-month median PFS in second-line HPV16/18-positive cervical cancer.

Most of the company's capital and attention since 2020, however, went to an adenoviral COVID-19 booster. It changed form three times and finally failed non-inferiority against Comirnaty by a wide margin in June 2026. The financial consequences are now clear:

  • An impairment of about KRW 162.

  • Equity down 28% in six months.

  • KRW 336 of short-term borrowings against KRW 130 of cash.

  • Revenue that comes from a bakery rather than medicine.

The Huniverse transaction is best understood as survival financing with a strategic narrative attached. Combining hospital-data infrastructure with personalised vaccines is a plausible long-term idea. But the acquirer is small (equity of KRW 8), has no development experience, and has not yet named product candidates or timelines. Value creation will depend on three things:

  1. Disciplined capital allocation. That likely means formally winding down the COVID-19 programme and refinancing or monetising the Magok asset.

  2. Advancing BVAC-C with a partner, ideally one that owns a checkpoint inhibitor.

  3. Converting GMP capacity into contracts with disclosed values.

At about KRW 2,215 the market prices Cellid at roughly 1.2x June 2026 book and 7.4x bakery-dominated sales. That premium to Korean peers appears driven by theme trading rather than fundamentals. On the evidence available, the risk/reward is unfavourable until three things happen: the deal closes, the post-closing capital structure is disclosed, and a credible, funded registrational plan for BVAC-C is presented.

Stance: Negative / high-risk speculative. The view should be re-assessed on deal closing and on the Q3 2026 balance sheet.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation

Kang Chang-yul (강창율)

Founder, CEO and largest shareholder (until the Huniverse closing)

Since 2006

Professor at SNU College of Pharmacy. Founding member of IDEC Pharmaceuticals (now Biogen) and contributor to the development of Rituxan.

Individual pay not disclosed in sources reviewed. Korean rules require disclosure only above KRW 5 a year.

Oh Tae-kwon (오태권)

Head of research institute

Named at the 2019 IPO

——

Kang Su-yeon (강수연)

Managing director (전무)

Named at the 2019 IPO

——

Jang Kyung-hee (장경희)

Executive director (상무)

Named at the 2019 IPO

——

Jung Se-hyun (정세현)

Executive director, management support

Named in a July 2022 filing

——

Kim Min-su (김민수)

Head of IR/finance team

Named in a 2020 release

——

“—” = not publicly disclosed.

Major Shareholders

HolderStakeDate / source

Kang Chang-yul

19.42%

End-2019 (DailyPharm)

Kang Chang-yul (with related parties)

15.02% (21.1%)

May 2024 (Smart Today; Asiae)

Kang Chang-yul

8.27%

30 Jun 2026 (DailyPharm)

Minority shareholders (30,678 holders)

89.03%

31 Dec 2025 (FY2025 business report via ETFShopping)

Foreign investors

0.93%

Sep 2026 (Alpha Distillery)

Huniverse Global (pro forma)

About 13.5%

Derived: 4,796,163 shares out of about 35.63M post-issuance shares (29.50M + 1.33M + 4.80M). The final figure depends on the CB and any other issuance.

Kang Chang-yul (pro forma)

About 6.9%

Derived

Centrust Investment Association / SPE Partners Investment Association

About 1.9% each (666,666 shares each)

Derived from the 22 Sep 2026 allotment

Competitive Landscape

Competitors by Segment

SegmentCompetitorCountryRelevant asset / position

HPV-driven cancer therapeutic vaccines

Genexine

Korea

GX-188E (HPV DNA vaccine) combined with a PD-1 inhibitor in cervical cancer. The most direct Korean comparator.

HPV-driven cancer therapeutic vaccines

Inovio Pharmaceuticals

US

VGX-3100 / INO-3107 HPV DNA immunotherapies

HPV-driven cancer therapeutic vaccines

ISA Pharmaceuticals

Netherlands

ISA101b synthetic long-peptide HPV16 vaccine + PD-1

HPV-driven cancer therapeutic vaccines

PDS Biotechnology

US

PDS0101 HPV16 vaccine in head-and-neck cancer

Personalised neoantigen vaccines

Moderna / Merck

US

mRNA-4157 (intismeran autogene)

Personalised neoantigen vaccines

BioNTech / Genentech

Germany / US

Autogene cevumeran

Cell-based immuno-oncology (Korea)

Eutilex

Korea

Immune-cell therapy (cited as a peer)

Cell-based immuno-oncology (Korea)

VaxCell-Bio, GC Cell

Korea

NK / cell therapies

Oncolytic / immuno-oncology (Korea)

SillaJen, PharmAbcine, ImmuneOncia

Korea

Peers in Korean immuno-oncology trading baskets

COVID-19 vaccines

Pfizer/BioNTech, Moderna, Novavax, SK bioscience (SKYCovione), EuBiologics

Global / Korea

Approved incumbents. Pfizer's Comirnaty was the Phase 3 comparator Cellid failed against.

Viral-vector CDMO (Korea)

Binex, AltiCure, SK pharmteco, ENCell, CHA Biotech's affiliates

Korea

Competitors (and partners) in the CDMO market

Key Competitors

CompanyTickerP/B (x)P/S (x)Operating margin (%)Note

Cellid

299,6601.427.58-128.3

Phase 3 failed; revenue is mostly bakery

Genematrix (진매트릭스)

109,8201.153.5-25.4

COVID-19 diagnostics residual

Eutilex

263,0500.715.2-180.3

Immune-cell therapy; clinical delays

SillaJen

215,6000.853.2

Near breakeven

Oncolytic virus

PharmAbcine

208,3401.023.3-95.1

Early immuno-oncology

Peer median

—0.933.8-95—

Company Snapshot

49

Employees

2006

Founded

SWOT Analysis

Strengths

  • Best-in-platform clinical data. BVAC-C + durvalumab achieved ORR 37.9% (5 CR, 6 PR), median PFS 8.7 months and 6-month PFS 51.7% in second-line HPV16/18+ cervical cancer. Grade 3–4 AEs occurred in 13% of patients (SGO 2025).
  • Acceptable safety across a large adenoviral dataset. No serious adverse drug reactions were reported in the about 3,000–4,000-subject COVID-19 Phase 3 (Jun 2026). Safety data is reusable for the vector platform.
  • Own GMP infrastructure. The Seongnam GMP centre has been operational since about 2020 and is capable of producing viral vectors and cell and gene therapies (MedigateNews, Jun 2025).
  • Tangible asset base. PP&E was KRW 607.8 at June 2026, including land at KRW 233.8 and the Magok building at KRW 366.9. This supports book value of KRW 536.7.
  • Big-pharma-style validation. The LG Chem licence (2021) carries up to KRW 1,825 in milestones plus royalties.
  • Record of accessing capital. About KRW 1,349 raised since the IPO, including a 97.6% existing-shareholder take-up in 2025.

Weaknesses

  • Lead asset failed. The Phase 3 GMT ratio of 0.42 sits far below the 0.67 non-inferiority margin, and seroresponse was 17.12% vs. 42.64% (Jun 2026).
  • No pharmaceutical revenue. About 99.97% of FY2025 revenue came from bakery e-commerce. Drug revenue was zero in FY2023.
  • Persistent losses. Operating losses ran from KRW −113 to −149 every year in FY2021–FY2025. The TTM net loss to June 2026 was about −274.
  • Liquidity. Current ratio 0.57x and short-term borrowings of KRW 336.3 against cash of KRW 129.7 (June 2026).
  • Heavy dilution. Shares rose from 10.71M to 29.50M (FY2022–FY2025), with about 6.13M more pending. The founder's stake fell from 19.42% to 8.27%.
  • Execution track record. Repeated changes of candidate and strategy (vector change in 2021, Phase 2b terminated in 2022, Omicron pivot in 2023). The 2019 out-licensing timetable was missed.

Opportunities

  • Registrational path for BVAC-C + checkpoint inhibitor in second-line cervical cancer, supported by DURBAC response durability.
  • Data-driven personalised vaccines using Huniverse's hospital information systems and medical data infrastructure (stated deal rationale, Sep 2026).
  • CDMO monetisation of under-used GMP capacity through AltiCure and further clients.
  • LG Chem milestones if BVAC-Neo enters the clinic. Up to KRW 1,825 is contingent.
  • Government grants, e.g. the national project selection for BVAC-E6E7 Phase 1 in head-and-neck cancer.
  • Monetising the Magok asset (sale, sale-and-leaseback or subleasing) to cut short-term debt. This is an analytical option, not a company plan.

Threats

  • Financing failure. If the Huniverse payment (due 9 Nov 2026) or the follow-on CB falls through, liquidity would come under acute pressure.
  • Further impairments. KRW 147.0 of capitalised development costs remains at June 2026, and the split by programme is undisclosed.
  • Regulatory. The LP.8.1 IND was rejected, and future COVID-19 trials need new designs.
  • Listing-maintenance risk. Losses before tax have been large relative to equity, and the revenue threshold depends on a low-margin bakery.
  • Competitive obsolescence. Global mRNA neoantigen and HPV vaccine programmes are moving ahead of BVAC-Neo and BVAC-C.
  • Theme-driven volatility. Moves of ±30% a day in June–September 2026 on COVID-19 or immuno-oncology themes distort price discovery and may complicate new issue pricing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
18 Mar 2025Board approves a KRW 241.5 shareholder rights offering (8.4M shares at a preliminary KRW 2,875)Fourth consecutive year of equity dilution. Minority shareholders object.
Mar 2025AGM: CEO apologises for three consecutive rights offerings and outlines a Phase 3 interim analysis and conditional-approval planGovernance and communication
Mar 2025DURBAC Phase 2 data at SGO 2025: ORR 37.9%, median PFS 8.7 monthsBest clinical evidence for the platform
Late Apr 2025Founder discloses a plan to sell 264,120 shares to fund rights participationFounder stake dilution
30 Apr 2025FSS declares the registration effective after focused reviewRegulatory hurdle cleared
May 2025Shares rise about 170% on COVID-19 resurgence in Greater China; lead manager LS Securities raises its underwriting fee mid-dealTheme-driven volatility
Jun 2025Rights offering priced at KRW 4,260. Existing shareholders subscribe 97.6%; public tranche 477.2:1; about KRW 358 raised.Largest post-IPO raise
16 Jun 2025MOU with AltiCure on a viral-vector CDMO solutionCDMO pivot begins
20 Jun 2025Press highlights that 99.8% of Q1 2025 revenue came from bakery e-commerceQuestions about the "bio" identity
Early Jul 20258.4M new shares listed; the stock trades close to the issue priceOverhang
FY2025 (reported Mar 2026)FY2025 revenue KRW 88.4 (+112%), operating loss KRW 113, net loss KRW 121, operating cash flow KRW −102Losses persist
30 Mar 2026Magok new facility investment disclosureCapital commitment
–LP.8.1 booster Phase 2 IND filedPipeline extension
–LP.8.1 Phase 2 IND returned/rejectedRegulatory setback
30 Apr 2026Magok investment finalised at KRW 235.4 (104.93% of the referenced equity base)Facility completed
30 Apr 2026Share price KRW 3,180; market cap about KRW 953Pre-readout level
18 Jun 2026Company publicly plans an MFDS approval filing based on Phase 3Expectation set
26 Jun 2026Phase 3 of AdCLD-CoV19-1 OMI misses non-inferiority (GMT ratio 0.42; SRR 17.12% vs 42.64%). Safety acceptable.Lead asset fails
26 Jun 2026Shares rise more than 14% on the day of the announcementSpeculative mispricing
29 Jun 2026Shares hit limit-down (−29.98%) to about KRW 1,950Market reprices
Jul 2026Shareholder meeting planned to explain the supplementary trial strategyStrategy reset
H1 2026 (reported Aug–Sep 2026)About KRW 162 of impairment (derived); equity falls to KRW 536.7; short-term borrowings KRW 336.3; cash KRW 129.7Liquidity strain
20 Jul 2026Shares near a 52-week low of about KRW 1,071Trough
27 Jul 2026Limit-up (+29.94%) to KRW 1,367 on a COVID-19 resurgence themeTheme volatility
29 Jul 2026Intraday KRW 2,245; volume 8.85M versus a 0.81M three-month averageSpeculative trading
2 Sep 2026AltiCure stability-testing and storage contract (value not disclosed)First CDMO contract after the MOU
13–15 Sep 2026Sector rotation; shares move with immuno-oncology themes (ImmuneOncia limit-up)Theme-driven trading
21 Sep 2026Change-of-control agreement with Huniverse Global (KRW 100; 4,796,163 shares)Control transfer
22 Sep 2026KRW 30 third-party allotment to Centrust and SPE Partners; shares hit limit-up on the change-of-control newsAdditional liquidity
2 Oct 2026Small-amount public offering filing; amended rights-offering decisionFurther capital raising
5 Oct 2026BizWatch places Cellid among about eight technology-listed biotechs changing their largest shareholder in 2026Sector context
15 Oct 2026Close of KRW 2,215 (−4.1%)Current

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment (KRW): Total revenue rose from KRW 9.1 in FY2021 to KRW 88.4 in FY2025.
Cellid, Co., Ltd. — Revenue by Segment (KRW)
Series (KRW)FY2021FY2022FY2023FY2024FY2025
Total revenue9.14.8041.788.4
E-commerce (bakery) revenue00038.188.4
Bio / CMO revenue9.14.803.60

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. DailyPharm — "코로나 백신 3상 고배…1300억 조달한 셀리드, 주인 바뀐다" (28 Sep 2026) (dailypharm.com)
  2. BizWatch — "특례상장 바이오, 주인이 바뀐다" (5 Oct 2026) (news.bizwatch.co.kr)
  3. NewDaily — Phase 3 non-inferiority failure and limit-down (29 Jun 2026) (biz.newdaily.co.kr)
  4. StockHub / Hankyung summary of the limit-down (Jun 2026) (stockhub.kr)
  5. Asiae — KRW 30 third-party allotment (22 Sep 2026) (core.asiae.co.kr)
  6. Seoul Economic Daily (DART relay) — amended Magok facility investment (30 Apr 2026) (sedaily.com)
  7. Valueline — balance sheet (separate, through 2026/06) (valueline.co.kr)
  8. Valueline — income statement (TTM through 2026/06) (valueline.co.kr)
  9. Valueline — cash flow (valueline.co.kr)
  10. Bullstory (OpenDART) — annual financials FY2017–FY2025 (bullstory.io)
  11. Bullstory — FY2025 detail (bullstory.io)
  12. ETFShopping — company, shareholders, employees (FY2025 business report) (etfshopping.com)
  13. ETFShopping — financial summary (etfshopping.com)
  14. Butler.works — 5-year summary and recent filings list (butler.works)
  15. Alpha Distillery — AI research, Sep 2026 (independent, non-brokerage) (alphadistill.com)
  16. Alpha Distillery — AI research, Aug 2026 (alphadistill.com)
  17. Alpha Distillery — AI research, Sep 2026 (CDMO / LG Chem) (alphadistill.com)
  18. Sidae — bakery revenue share (Jun 2025) (sidae.com)
  19. Dealsite — bakery acquisition rationale (Mar 2024) (dealsite.co.kr)
  20. Dealsite — zero revenue and pipeline focus (Mar 2024) (dealsite.co.kr)
  21. Dealsite — quarterly bonus controversy (Mar 2024) (dealsite.co.kr)
  22. Dealsite — cash position and Magok PF (Oct 2023) (dealsite.co.kr)
  23. Dealsite — Binex CMO (Aug 2021) (dealsite.co.kr)
  24. MTN — CEO comments on ForBaker (Jun 2024) (news.mtn.co.kr)
  25. Smart Today — 2024 rights offering and founder stake (smarttoday.co.kr)
  26. Asiae — 2024 rights offering (core.asiae.co.kr)
  27. MedigateNews — 2024 issue price (medigatenews.com)
  28. MedigateNews — 2024 subscription result (medigatenews.com)
  29. Hankyung — 2025 FSS approval (hankyung.com)
  30. Asiae — 2025 rights offering outcome (Jul 2025) (core.asiae.co.kr)
  31. Daum / Asiae — underwriting fee change (May 2025) (v.daum.net)
  32. TheBell / Money Today — founder share sale (May 2025) (mt.co.kr)
  33. VentureSquare — 2023 rights offering and Phase 3 IND (venturesquare.net)
  34. MedigateNews — AltiCure MOU (Jun 2025) (medigatenews.com)
  35. BioSpectator — LG Chem licence (May 2021) (biospectator.com)
  36. Company release via AlphaSquare — LG Chem licence (May 2021) (file.alphasquare.co.kr)
  37. Company release via AlphaSquare — Andong production MOU (Jul 2020) (file.alphasquare.co.kr)
  38. BioSpectator — Syntekabio MOU (May 2019) (biospectator.com)
  39. BioSpectator — BVAC-B Phase 1 (biospectator.com)
  40. BioSpectator — ASCO 2021 BVAC-C Phase 2a: biospectator.com:443
  41. BioSpectator — IPO pricing (biospectator.com)
  42. BioSpectator — listing day (biospectator.com)
  43. BioSpectator — listing approval (biospectator.com)
  44. BioSpectator — KOSDAQ filing (biospectator.com)
  45. Financial News — IPO and 2014 NeoImmuneTech licence (fnnews.com)
  46. DailyPharm — IPO plans (Jan 2019) (dailypharm.com)
  47. EKN — retail subscription (Feb 2019) (m.ekn.kr)
  48. ASCO Post — DURBAC at SGO 2025 (ascopost.com)
  49. CancerNetwork — DURBAC results (cancernetwork.com)
  50. Yonsei repository — DURBAC abstract (ir.ymlib.yonsei.ac.kr)
  51. Frontiers in Immunology (2024) — BVAC-C Phase I/IIa (frontiersin.org)
  52. IRGO — Cellid IR room (DART disclosure titles incl. LP.8.1 IND) (m.irgo.co.kr)
  53. Investing.com — price and market cap data (Jul–Aug 2026) (in.investing.com)
  54. Simply Wall St — company profile (simplywall.st)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.